Media ReleasesImugene Limited

View All Imugene Limited News

Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer

  • First patient dosed in 68 patient Randomised Phase 2 HER-Vaxx cancer trial
  • Two Eastern European sites now actively recruiting
  • Approval imminent for trial sites in Hong Kong, Taiwan, Thailand and India

SYDNEY, Australia, 14 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced dosing of the first patient in an open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

For further information please download PDF attached:
  Download this document